Alimera Sciences, Inc.

NasdaqGM:ALIM 주식 리포트

시가총액: US$301.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alimera Sciences 과거 순이익 실적

과거 기준 점검 0/6

Alimera Sciences 의 수입은 연평균 -37.8%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 9.4%의 비율로 증가했습니다. 매출은 연평균 10.3%의 비율로 증가해 왔습니다.

핵심 정보

-37.79%

순이익 성장률

-16.04%

주당순이익(EPS) 성장률

Pharmaceuticals 산업 성장률5.95%
매출 성장률10.30%
자기자본이익률-37.89%
순이익률-15.32%
최근 순이익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Seeking Alpha • Sep 11

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Summary Alimera Sciences, Inc. is being acquired by ANI Pharmaceuticals for $5.50 per share, with a contingent value right, or CVR, potentially adding up to $0.50 per share. Despite initial delays and Alimera suing ANI to close the deal, ANI remains committed, expecting to resolve closing conditions promptly. The deal is highly synergistic, adding durable assets to ANI's portfolio, with significant revenue growth and accretion expected by 2025. At $5.54 per share, Alimera Sciences stock is attractive, offering potential CVR payouts based on achievable sales targets, making it a compelling investment. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Alimera Sciences: Cheap CVR Optionality

Summary Alimera Sciences is being acquired by a larger peer at $5.5/share + CVR of up to 50 cents. In this article, I will focus on a CVR play with only a 10-cent outlay and a potential payout of up to 50 cents. The merger-related risks are minimal, and there are arguments that suggest the CVR milestones could be met. Read the full article on Seeking Alpha
분석 기사 • Jun 18

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

You may think that with a price-to-sales (or "P/S") ratio of 1.9x Alimera Sciences, Inc. ( NASDAQ:ALIM ) is a stock...
분석 기사 • Feb 15

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right...
분석 기사 • Dec 30

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Oct 13

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

There wouldn't be many who think Alimera Sciences, Inc.'s ( NASDAQ:ALIM ) price-to-sales (or "P/S") ratio of 2.5x is...
분석 기사 • Sep 13

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Oct 06

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Alimera Sciences (NASDAQ:ALIM) said on Thursday a post-hoc analyses from a Phase 4 study showed that median treatment frequency in diabetic macular edema patients treated with its therapy Iluvien 0.19 mg was lower than from patients on other regimens. Iluvien provides diabetic macular edema patients with continuous therapy for up to 36 months. The treatment significantly reduced the number of eyes requiring anti-VEGF, corticosteroid, and laser therapy and reduced the total number of therapies administered by 46%. Iluvien is a intravitreal implant in the United States for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Seeking Alpha • Sep 20

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Ireland. ALIM said the reimbursement was granted to the its Ireland-based European unit by the Health Service Executive Corporate Pharmaceutical Unit and National Centre for Pharmacoeconomics in Ireland. The reimbursement decision by Ireland adds to a string of such grants earlier this year by Portugal, France and Italy. "We continue to expand the availability of our non-infectious uveitis indication in our International Segment with it now accessible to patients in all of our direct markets in addition to our key distributor markets," ALIM CEO Rick Eiswirth said in a statement. ALIM stock closed -3.6% at $5.38 on Monday.
Seeking Alpha • Aug 09

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Tuesday said it had been granted reimbursement for its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in Portugal. ALIM said the reimbursement was granted by Portugal's National Authority of Medicines and Health Products with no change to the current label. The reimbursement decision by Portugal follows similar approvals for Iluvien in France and Italy in July. “This summer has been a productive one for expanding availability of our non-infectious uveitis indication in our International Segment with it soon to be accessible to patients in all of our direct markets in addition to our key distributor markets,” ALIM CEO Rick Eiswirth said in a statement. ALIM said it is planning to launch Iluvien in Portugal and France in Q3. Alimera (ALIM) stock closed +2.6% at $7.18 on Monday.
Seeking Alpha • Jul 22

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Alimera Sciences (NASDAQ:ALIM) on Friday said it would launch its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in France through its distribution partner Horus Pharma. ALIM said Horus had been granted pricing and reimbursement approval for Iluvien for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Economics Committee for Health Products. Alimera (ALIM) did not disclose the pricing determination for Iluvien. Earlier in July, ALIM got Italian regulatory approval and was granted pricing and reimbursement for Iluvien for the same indication. ALIM stock closed +0.8% at $5.33 on Thursday.
Seeking Alpha • Jul 08

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Alimera Sciences (NASDAQ:ALIM) has got Italian regulatory approval for its Iluvien injection for the treatment of uveitis, a form of eye inflammation. ALIM's Ireland-based European unit, Alimera Sciences Europe, got an approval and was granted pricing and reimbursement for Iluvien by the Italian Medicines Agency (AIFA), Alimera said in a statement on Friday. The indication was for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. ALIM said it would launch Iluvien through its Italian distribution partner, ophthalmic company SIFI. It did not disclose the pricing determination for Iluvien. ALIM stock closed marginally higher at $5.32 on Thursday.
분석 기사 • Mar 24

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Nov 06

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Alimera Sciences, Inc...
분석 기사 • Aug 24

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Even though Alimera Sciences, Inc. ( NASDAQ:ALIM ) posted strong earnings recently, the stock hasn't reacted in a large...
분석 기사 • Feb 11

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Alimera Sciences, Inc. ( NASDAQ:ALIM ) shareholders will doubtless be very grateful to see the share price up 97% in...

매출 및 비용 세부 내역

Alimera Sciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGM:ALIM 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
30 Jun 24100-155417
31 Mar 2490-235117
31 Dec 2381-214617
30 Sep 2368-214116
30 Jun 2359-254017
31 Mar 2356-173917
31 Dec 2254-183916
30 Sep 2254-184016
30 Jun 2253-173915
31 Mar 2260-73814
31 Dec 2159-43614
30 Sep 2159-13413
30 Jun 215923312
31 Mar 2147-83110
31 Dec 2051-53210
30 Sep 2054-43410
30 Jun 2055-63610
31 Mar 2056-93911
31 Dec 1954-103911
30 Sep 1952-123811
30 Jun 1950193711
31 Mar 1950223711
31 Dec 1847173711
30 Sep 1841113811
30 Jun 1839-223811
31 Mar 1839-233711
31 Dec 1736-223610
30 Sep 1737-213810
30 Jun 1736-253910
31 Mar 1735-294311
31 Dec 1634-334512
30 Sep 1629-384413
30 Jun 1628-304314
31 Mar 1624-324215
31 Dec 1522-314215
30 Sep 1518-304114
30 Jun 1514-353714
31 Mar 1510-263212
31 Dec 148-372712
30 Sep 148-412411
30 Jun 146-36259
31 Mar 144-58269
31 Dec 132-51249
30 Sep 131-42268

양질의 수익: ALIM 은(는) 현재 수익성이 없습니다.

이익 마진 증가: ALIM는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: ALIM은 수익성이 없으며 지난 5년 동안 손실이 연평균 37.8% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 ALIM의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: ALIM은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: ALIM는 현재 수익성이 없으므로 자본 수익률이 음수(-37.89%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2024/09/18 16:14
종가2024/09/13 00:00
수익2024/06/30
연간 수익2023/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Alimera Sciences, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
James MolloyAlliance Global Partners
Andrew D'SilvaB. Riley Securities, Inc.
Caroline CornerCantor Fitzgerald & Co.